Recruiting Status: Recruiting
Age: 18 – 65 Years Old
The first-in-human Phase 1/Phase 2a study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
